156740-97-5

Basic information

• Product Name: 4-(4-methoxy-phenoxy)-3,5-dimethyl-nitrobenzene
• Synonyms: 4-(4-methoxy-phenoxy)-3,5-dimethyl-nitrobenzene
• CAS NO: 156740-97-5
• Molecular Weight: 273.288
• Mol File: 156740-97-5.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-methoxy-phenoxy)-3,5-dimethyl-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-methoxy-phenoxy)-3,5-dimethyl-nitrobenzene(156740-97-5)
• EPA Substance Registry System: 4-(4-methoxy-phenoxy)-3,5-dimethyl-nitrobenzene(156740-97-5)

Safety Data

• Hazardous Substances Data: 156740-97-5(Hazardous Substances Data)

Upstream product

• 2423-71-4 2,6-dimethyl-4-nitro phenol 
• 38560-96-2 2-chloro-1,3-dimethyl-5-nitro-benzene 
• 150-76-5 4-methoxy-phenol 
• 7440-44-0 pyrographite 

Downstream Products

• 156740-86-2 [5-(2,6-dimethyl-4-nitro-phenoxy)-2-methoxy-phenyl]-(4-fluoro-phenyl)-methanone 
• 355377-72-9 5-(2,6-dimethyl-4-nitro-phenoxy)-2-methoxy-benzaldehyde 

Relevant articles and documents

Thyromimetic organic compounds

Compounds of the present invention of the formula are thyromimetic agents which can be used to prevent and/or treat diseases associated with an imbalance of thyroid hormones, such as hypo- and hyper-thyroidism, obesity, osteoporosis and depression. The co

Indole carboxylic acids as thyroid receptor ligands

A compound of the formula wherein W, R1, R2, R3, R4, R5, R6, R7, R8 and R13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, th

Thyromimetic organic compounds

Compounds of the present invention of the formula are thyromimetic agents which can be used to prevent and/or treat diseases associated with an imbalance of thyroid hormones, such as hypo- and hyper-thyroidism, obesity, osteoporosis and depression. The co

Heteroacetic acid derivatives

Disclosed are compounds of formula STR1 wherein R is hydroxy, esterified hydroxy or etherified hydroxy; R1 is halogen, trifluoromethyl or lower alkyl; R2 is halogen, trifluoromethyl or lower alkyl; R3 is halogen, trifluoromethyl, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl or cycloalkyl-lower alkyl; or R3 is the radical STR2 wherein R8 is hydrogen, lower alkyl, aryl, cycloalkyl, aryl-lower alkyl or cycloalkyl-lower alkyl; R9 is hydroxy or acyloxy; R10 represents hydrogen or lower alkyl; or R9 and R10 together represent oxo; R4 is hydrogen, halogen, trifluoromethyl or lower alkyl; X is --NR7, S or O; W is O or S; R5 represents hydrogen, lower alkyl or aryl-lower alkyl;and R6 represents hydrogen; or R5 and R6 together represent oxo provided that X represents --NR7; R7 represents hydrogen or lower alkyl; Z represents carboxyl, carboxyl derivatized as a pharmaceutically acceptable ester or as a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; which are useful as hypocholesteremic agents.

Synthesis and Structure-Activity Relationships of Oxamic Acid and Acetic Acid Derivatives Related to L-Thyronine

Aryloxamic acids 7 and 23, (arylamino)acetic acids 29, arylpropionic acids 33, arylthioacetic acids 37, and (aryloxy)acetic acid 41 related to L-triiodothyronine (L-T3) were prepared and tested in vitro for binding to the rat liver nuclear L-T